SCHEMBL7533901

SCHEMBL7533901

COc1ccc(S(=O)(=O)c2ccc(OS(=O)(=O)c3ccccc3)c(C(=O)O)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
HTT P42858 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
KEAP1 Q14145 2/20 0.50
NFE2L2 Q16236 2/20 0.50
MAPT P10636 2/20 0.47
PKM P14618 2/20 0.47
ALDH1A1 P00352 1/20 0.47
POLB P06746 3/20 0.46
APEX1 P27695 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
TUBB4A P04350 1/20 0.46
TUBB P07437 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
TUBA1B P68363 1/20 0.46
TUBA4A P68366 1/20 0.46
TUBB4B P68371 1/20 0.46
TUBB3 Q13509 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7534275 0.86 SMN1; SMN2 (0.47) LMNASMN1; SMN2HTTMAPTALDH1A1
SCHEMBL7535488 0.85 MEN1 (0.49) LMNASMN1; SMN2HTTMAPTALDH1A1
SCHEMBL7540324 0.85 POLB (0.66) LMNAHTTMAPTPKMALDH1A1
SCHEMBL8237230 0.84 MAPK1 (0.54) LMNAL3MBTL1HTTALDH1A1POLB
SCHEMBL8962292 0.80 POLB (0.68) L3MBTL1SMN1; SMN2HTTTDP1MAPT
SCHEMBL8846893 0.78 KDM4E (0.53) LMNAL3MBTL1SMN1; SMN2HTTTDP1
SCHEMBL2900381 0.76 PKM (0.83) SMN1; SMN2HTTPKMALDH1A1POLB
SCHEMBL7537023 0.75 LMNA (0.61) LMNAL3MBTL1SMN1; SMN2HTTMAPT
SCHEMBL11775991 0.75 MAPT (0.47) LMNAL3MBTL1SMN1; SMN2HTTTDP1
SCHEMBL343849 0.75 KMT2A (0.53) L3MBTL1HTTMAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 LMNA 2006/4885L3MBTL1 1938/4885SMN1; SMN2 4446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.